Taken together, these results provide compelling in vivo evidence that furin promotes CRC tumor growth, at least in part through the TGF-β/ERK signaling pathway, underscoring its potential as a therapeutic target to limit tumor progression and chemoresistance. Here, FURIN is linked to colorectal carcinoma.